Respiratory Syncytial Virus

Less than half of respondents would recommend a vaccine against respiratory syncytial virus to a pregnant friend or family member.

The new RSV vaccines are expected to be available in fall 2023.

Ryan Haumschild, PharmD, MS, MBA, leads a panel of medical experts in a discussion regarding adult RSV vaccination.

Findings suggest that psychometric tests used for The Respiratory Infection Intensity and Impact Questionnaire provide reliable, construct validity, and responsive evidence to detect onset symptoms of RSV.

CDC Advisory Committee on Immunization Practices recommends the use of respiratory syncytial virus (RSV) vaccine, adjuvanted (Arexvy) for adults 60 years of age and older based on findings from the first season of the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial.

A single dose of Arexvy was found effective preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older across 2 full RSV seasons.

Adult and maternal RSV vaccines reveal positive findings.

A broader understanding of vaccine hesitancy and barriers has helped to enhance acceptance of vaccination services through educational outreach.

Study investigators said that understanding how the human immune response relates to respiratory syncytial virus infection has been a major obstacle for vaccine development.

The CDC has recommended a follow-up nucleic acid amplification test to be used for patients clinically suspected to have influenza, despite a negative POC test.

Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Nanoparticles could improve the solubility of drugs, aid in treatment escape from the immune system, and increase the half-life of drugs in the circulatory system against viral lung infections such as influenza, coronavirus, and respiratory syncytial virus.

Study finds that a more accurate estimate of the burden of RSV disease will facilitate appropriate decision making regarding the use of preventive interventions, such as vaccination.

Hospitalization costs from respiratory syncytial virus infection are driven by older age and comorbidities.

The 2022-2023 COVID-19 season did not have a significant surge of COVID-19 like it did early on in the COVID-19 pandemic.

Vaccination is especially important for older adults with any chronic health conditions because vaccines can prevent serious illness and resulting complications down the road.

Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Results of a review show that lessons learned from the pandemic apply to the respiratory syncytial virus.

Atypical respiratory syncytial virus epidemics may continue, and testing patients for multiple respiratory pathogens when indicated might be necessary.

Respiratory syncytial virus (RSV) vaccine demonstrated efficacy of 66.7% in reducing RSV-associated lower respiratory tract illness with at least 2 signs or symptoms in older adults.

State-level respiratory syncytial virus hospitalization rates for 2022 could be the highest seen since 2006, analysis published in Frontiers in Pediatrics indicate.

The trial did not meet the second primary efficacy endpoint of medically attended respiratory syncytial virus-associated lower respiratory tract illness.

Not only are pharmacists easily accessible to the public, they are also highly visible as a source for travel immunization services.

The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.

Prior to the pandemic, the seasonality of respiratory syncytial virus followed a pattern; now, this pattern of disease spread has changed significantly.

The test did not reach the World Health Organization’s minimum performance requirement, which is 80% sensitivity for SARS-CoV-2, in the study population.

Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.

Interventions targeting respiratory viruses should be considered as a means of protecting against invasive pneumococcal disease in children, study finds.

The FDA set a Prescription Drug User Fee Act for May 2023 for Pfizer’s respiratory syncytial virus bivalent vaccine candidate.

Phase 3 trial results indicate efficacy against respiratory syncytial virus-lower respiratory tract disease in individuals aged 60 years and older.